Cargando…

Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening

BACKGROUND: Refugees are at increased risk of developing tuberculosis (TB) soon after resettlement. Targeting high-risk populations for latent tuberculosis infection (LTBI) screening and treatment is an important measure towards eliminating TB in low incidence countries, however, there are low rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, R. K., Talavlikar, R., Chiazor, O., Bietz, J., Gardiner, H., Fisher, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431896/
https://www.ncbi.nlm.nih.gov/pubmed/34503458
http://dx.doi.org/10.1186/s12879-021-06637-z
_version_ 1783751042451636224
author Lim, R. K.
Talavlikar, R.
Chiazor, O.
Bietz, J.
Gardiner, H.
Fisher, D.
author_facet Lim, R. K.
Talavlikar, R.
Chiazor, O.
Bietz, J.
Gardiner, H.
Fisher, D.
author_sort Lim, R. K.
collection PubMed
description BACKGROUND: Refugees are at increased risk of developing tuberculosis (TB) soon after resettlement. Targeting high-risk populations for latent tuberculosis infection (LTBI) screening and treatment is an important measure towards eliminating TB in low incidence countries, however, there are low rates of screening and treatment completion in the LTBI cascade of care. The authors hypothesized that an interferon-gamma release assay (IGRA) screening strategy would lead to a higher proportion of refugees completing LTBI screening and treatment, compared to sequential screening with tuberculin skin test (TST) and confirmatory IGRA. METHODS: This retrospective cohort study included eligible refugees screened with a sequential strategy versus a solo-IGRA strategy at different time periods from a centralized refugee clinic. The primary outcome was the proportion completing LTBI screening in each cohort. RESULTS: A total of 471 subjects were included (240 in sequential screening, 231 in solo-IGRA screening). 54% of refugees completed LTBI screening with sequential testing, compared to 85% of those screened with a solo-IGRA. Time to completing screening was also shorter in the solo-QFT group (difference 16.5 days, p < 0.01, 95% confidence interval 9.3, 23.7). There was a higher incidence of LTBI diagnosis in the solo-IGRA group (41 versus 20, p = 0.002). Screening completion was predicted by solo-IGRA screening (aOR 3.74, 95% confidence interval 2.30, 6.09; p < 0.001) and if refugees were privately-sponsored (aOR 2.81, 95% confidence interval 1.53, 5.15; p = 0.001). Treatment completion rates did not differ between groups. CONCLUSION: This study has identified fewer dropouts in the LTBI cascade of care if a solo-IGRA strategy is used for screening. An IGRA should be strongly considered as the screening method for refugees arriving in low-incidence settings if resources are available.
format Online
Article
Text
id pubmed-8431896
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84318962021-09-10 Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening Lim, R. K. Talavlikar, R. Chiazor, O. Bietz, J. Gardiner, H. Fisher, D. BMC Infect Dis Research BACKGROUND: Refugees are at increased risk of developing tuberculosis (TB) soon after resettlement. Targeting high-risk populations for latent tuberculosis infection (LTBI) screening and treatment is an important measure towards eliminating TB in low incidence countries, however, there are low rates of screening and treatment completion in the LTBI cascade of care. The authors hypothesized that an interferon-gamma release assay (IGRA) screening strategy would lead to a higher proportion of refugees completing LTBI screening and treatment, compared to sequential screening with tuberculin skin test (TST) and confirmatory IGRA. METHODS: This retrospective cohort study included eligible refugees screened with a sequential strategy versus a solo-IGRA strategy at different time periods from a centralized refugee clinic. The primary outcome was the proportion completing LTBI screening in each cohort. RESULTS: A total of 471 subjects were included (240 in sequential screening, 231 in solo-IGRA screening). 54% of refugees completed LTBI screening with sequential testing, compared to 85% of those screened with a solo-IGRA. Time to completing screening was also shorter in the solo-QFT group (difference 16.5 days, p < 0.01, 95% confidence interval 9.3, 23.7). There was a higher incidence of LTBI diagnosis in the solo-IGRA group (41 versus 20, p = 0.002). Screening completion was predicted by solo-IGRA screening (aOR 3.74, 95% confidence interval 2.30, 6.09; p < 0.001) and if refugees were privately-sponsored (aOR 2.81, 95% confidence interval 1.53, 5.15; p = 0.001). Treatment completion rates did not differ between groups. CONCLUSION: This study has identified fewer dropouts in the LTBI cascade of care if a solo-IGRA strategy is used for screening. An IGRA should be strongly considered as the screening method for refugees arriving in low-incidence settings if resources are available. BioMed Central 2021-09-09 /pmc/articles/PMC8431896/ /pubmed/34503458 http://dx.doi.org/10.1186/s12879-021-06637-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lim, R. K.
Talavlikar, R.
Chiazor, O.
Bietz, J.
Gardiner, H.
Fisher, D.
Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
title Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
title_full Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
title_fullStr Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
title_full_unstemmed Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
title_short Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
title_sort fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431896/
https://www.ncbi.nlm.nih.gov/pubmed/34503458
http://dx.doi.org/10.1186/s12879-021-06637-z
work_keys_str_mv AT limrk fewerlossesinthecascadeofcareforlatenttuberculosiswithsolointerferongammareleaseassayscreeningcomparedtosequentialscreening
AT talavlikarr fewerlossesinthecascadeofcareforlatenttuberculosiswithsolointerferongammareleaseassayscreeningcomparedtosequentialscreening
AT chiazoro fewerlossesinthecascadeofcareforlatenttuberculosiswithsolointerferongammareleaseassayscreeningcomparedtosequentialscreening
AT bietzj fewerlossesinthecascadeofcareforlatenttuberculosiswithsolointerferongammareleaseassayscreeningcomparedtosequentialscreening
AT gardinerh fewerlossesinthecascadeofcareforlatenttuberculosiswithsolointerferongammareleaseassayscreeningcomparedtosequentialscreening
AT fisherd fewerlossesinthecascadeofcareforlatenttuberculosiswithsolointerferongammareleaseassayscreeningcomparedtosequentialscreening